JAK Inhibition by Methotrexate (And csDMARDs) May Explain Clinical Efficacy as Monotherapy and Combination Therapy
Journal of Leukocyte Biology - United States
doi 10.1002/jlb.5ru0519-145r
Full Text
Open PDFAbstract
Available in full text
Date
July 16, 2019
Authors
Publisher
Wiley